Contribute Try STAT+ Today

In an unusual step, the European Commission plans to intervene in the recent merger between Illumina (ILMN) and Grail because regulators were unable to finish reviewing the deal before it was completed, raising concerns that competition in the market for DNA sequencing tests will now be damaged.

The move comes one month after Illumina stunned regulators by announcing it had closed its $8 billion acquisition, even though the EC had opened an investigation only weeks earlier at the prompting of France and five other European Union member states. In the U.S., the Federal Trade Commission had already filed a complaint last March to block the deal.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment